Clinical Trials Browser

Leukemia, Myeloid, Acute

NCT07471815 2026-03-13

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05763199 2026-03-12

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Phase 2 Active not recruiting

20 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT01928589 2026-03-06

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Phase NA Active not recruiting

81 enrolled

Breast

Breast Neoplasms

NCT04262466 2026-03-06

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Active not recruiting

410 enrolled

Other solid neoplasm

Select Advanced Solid Tumors

NCT05710328 2026-03-02

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Phase 2 Active not recruiting

235 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04928807 2026-02-27

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Phase 3 Active not recruiting

231 enrolled

Gastrointestinal

Rectal Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

Phase 3 Active not recruiting

327 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03943173 2026-02-25

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Phase EARLY_PHASE1 Active not recruiting

15 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07429318 2026-02-24

GC/GEJC

Active not recruiting

300 enrolled

Gastrointestinal

Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Clinical Trials

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

NIRVANA-LUNG

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

GC/GEJC

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination